BOLT - Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies Including BDC-3042 | Benzinga
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of the first and foundational patent covering BDC-3042. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 11,753,474 titled "Anti-Dectin-2 Antibodies," on September 12, 2023.
"The issuance of this patent is an important milestone in protecting the composition of matter and methods of treatment for our BDC-3042 clinical candidate," explained Justin A. Kenkel, Ph.D., BDC-3042 co-inventor and Principal Scientist at Bolt Biotherapeutics. "This patent covers antibodies with a novel mechanism of action that leverages Dectin-2 agonism to repolarize tumor-associated macrophages into immunostimulatory, anti-tumor macrophages. We are on track to enter the clinic with BDC-3042 this year and are excited by the potential for this new approach to treat many different types of cancer."
The claims of the patent will be valid through May 2041, excluding any patent term adjustments or extensions which may provide additional protection.
About BDC-3042
Bolt Biotherapeutics' myeloid-modulating antibody, BDC-3042, leverages the power of myeloid cells to stimulate anti-tumor activity. BDC-3042 is an agonist antibody targeting Dectin-2, an immune-activating pattern recognition receptor expressed by tumor-associated macrophages (TAMs) which are frequently found in the tumor microenvironment. TAMs play a key role in establishing an immunosuppressive tumor microenvironment conducive to tumor survival and progression. BDC-3042 activates Dectin-2, leading to production of an array of pro-inflammatory cytokines and chemokines and repolarization of TAMs into immunostimulatory "M1" macrophages. ...